Here’s a startling fact: giving toddlers two doses of the flu vaccine could be the game-changer we’ve been missing in the fight against influenza. But here’s where it gets controversial—while this approach significantly boosts protection, it’s only truly effective for children under three, leaving older kids with less dramatic results. Why? That’s the million-dollar question researchers are still unpacking.
A groundbreaking systematic review and meta-analysis published in JAMA Network Open (http://www.doi.org/10.1001/jamanetworkopen.2025.35250) reveals that for children who’ve never been vaccinated against the flu, two doses of the inactivated flu vaccine offer better protection than a single dose—but only in the youngest age group. Led by Jessie Goldsmith, a PhD student at the University of Melbourne’s Doherty Institute, the study analyzed 51 trials involving over 400,000 participants. The findings? A second dose in the first year of vaccination increased effectiveness by 15 percentage points for kids under nine and a whopping 28 percentage points for those under three.
And this is the part most people miss: in real-world scenarios, vaccine effectiveness against any flu strain jumped from 35% to 43% after two doses in children under nine. But for toddlers under three, the numbers were even more striking—effectiveness soared from 14% to 41%. This raises a critical question: Why does the second dose pack such a punch for the youngest kids but not for their older peers?
Goldsmith suggests two key factors: younger children’s immune systems are still developing, and they’re less likely to have encountered the flu virus before. This makes their bodies more responsive to the vaccine’s double dose. However, as kids age, their immune systems mature, and prior exposure to the virus may reduce the added benefit of that second shot.
The World Health Organization (WHO) and the American Academy of Pediatrics (https://www.aap.org/?srsltid=AfmBOorAzupNAnx9QhILZFobNt2SMsjweuVpPro9eyJ7n-Oon0fE5z73) already recommend two doses for vaccine-naive children under nine, spaced at least four weeks apart. But here’s the twist: immunogenicity studies show that two doses help young children reach the same protective threshold as adults, yet research specifically validating this threshold in kids remains limited. Is this enough to justify the two-dose approach for all?
The study also highlights a gap in data for the live attenuated influenza vaccine (recommended for children aged two and up), making it tough to compare one-dose versus two-dose strategies. Early trials show promising results—82% efficacy with two doses versus 51% with one—but more research is needed.
So, what’s the takeaway? For now, two doses seem to be a no-brainer for toddlers, but the science isn’t as clear for older kids. What do you think? Is the two-dose strategy worth it for all children, or should we focus on the youngest age group? Let’s keep the conversation going in the comments—your perspective could spark the next big debate in flu prevention.
